Literature DB >> 10998546

Effects of an antisense oligonucleotide to pronociceptin and long-term prevention of morphine actions by nociceptin.

S Candeletti1, S Ferri.   

Abstract

To further characterize the anti-opioid action of the neuropeptide nociceptin, we examined the effects of the repeated intracerebroventricular (i.c.v.) treatment (once daily for 4 days) with an antisense oligodeoxynucleotide complementary to pronociceptin mRNA, in the rat. We also investigated possible changes of the antinociceptive and hyperthermic effects induced by the i.c.v. administration of morphine, in rats i.c.v. pretreated with nociceptin 3 h before. The pretreatment with the antisense oligodeoxynucleotide, but not with a mismatched sequence (used as a control), caused an increase in spontaneous locomotor activity and produced a potentiation of the antinociceptive effect of a submaximal dose of i.c.v. morphine (1 microgram/rat). The i.c.v. pretreatment with nociceptin (2 nmol/rat, 3 h before) prevented both the antinociceptive and the hyperthermic effects of morphine (10 microgram/rat i.c.v.). These results strengthen the hypothesis of an anti-opioid action of nociceptin at supraspinal level and suggest that the neuropeptide may exert long-term modulatory effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998546     DOI: 10.1016/s0196-9781(00)00249-7

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

Review 2.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

3.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

4.  Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Authors:  Matteo Marti; Flora Mela; Carlo Veronesi; Remo Guerrini; Severo Salvadori; Mauro Federici; Nicola B Mercuri; Anna Rizzi; Gianfranco Franchi; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.